Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.01851
European Journal of Endocrinology, Vol 152, Issue 2, 233-240
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yilmaz, M. I.
Right arrow Articles by Ozata, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yilmaz, M. I.
Right arrow Articles by Ozata, M.

CLINICAL STUDY

The association of plasma adiponectin levels with hypertensive retinopathy

Mahmut Ilker Yilmaz1, Alper Sonmez2, Selim Kilic3, Turgay Celik4, Necati Bingol6, Murat Pinar2, Tarkan Mumcuoglu5 and Metin Ozata7

1 Departments of Nephrology, 2 Internal Medicine, 3 Epidemiology, 4 Cardiology and 5 Ophthalmology, Gülhane School of Medicine, 06 018 Etlik-Ankara, Turkey, 6 Department of Biochemistry, Bayindir Medical Center, Ankara, Turkey and 7 Department of Endocrinology and Metabolism, GATA Haydarpasa Training Hospital, 81020Acibadem, Istanbul, Turkey

(Correspondence should be addressed to M I Yilmaz; Email: mahmutiyilmaz{at}yahoo.com)

Objective: Previous studies have demonstrated that low plasma adiponectin concentrations are associated with essential hypertension. It has also recently been shown that adiponectin plays an essential role in the modulation of angiogenesis. These data led us to hypothesize that adiponectin might contribute to end-organ damage in hypertension.

Methods: In the present study we have evaluated the relationship between plasma adiponectin concentrations and hypertensive retinopathy. One hundred and ten patients newly diagnosed with essential hypertension (EHT) (mean age, 46.79±5.0 years; body mass index (BMI), 26.47±2.23 kg/m2; male/female ratio, 58/52) and 57 healthy normotensive control subjects (NT) (mean age, 46.84±5.4 years; BMI, 26.66±2.65 kg/m2; male/female ratio, 33/24) were enrolled.

Results: Plasma adiponectin levels were significantly lower in EHT than in NT (P < 0.001). In addition, adiponectin concentrations were strongly correlated with systolic and diastolic blood pressures in EHT (r = –0.757, P < 0.001; r = –0.761, P < 0.001) while there was no correlation in the NT group. Plasma adiponectin in patients with grade 0 hypertensive retinopathy (n = 52) was significantly higher than that of the patients with grade 1 (n = 30) and 2 (n = 28) hypertensive retinopathy (P < 0.001 for each). Plasma adiponectin in patients with grade 0 hypertensive retinopathy was also significantly lower than that in the NT group (P < 0.001). The estimated threshold of plasma adiponectin concentration for hypertensive retinopathy was 17 µg/ml. This critical adiponectin level served largely to separate patients with retinopathy from those without.

Conclusion: Our results have shown that plasma adiponectin concentrations decrease progressively with higher grades of hypertensive retinopathy even after correction for other atherogenic risk factors, suggesting that a critical adiponectin level is needed for the development of retinopathy.




This article has been cited by other articles:


Home page
HypertensionHome page
G. Bakris
Proteinuria: A Link to Understanding Changes in Vascular Compliance?
Hypertension, September 1, 2005; 46(3): 473 - 474.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.